International Sourcing

Retatrutide activates three hormone receptors: GLP‑1, GIP, and glucagon.

This triple action is unique compared to drugs that target only GLP‑1 or GLP‑1 + GIP

In the Phase 2 obesity trial, retatrutide caused very large weight loss.At the highest tested dose (12 mg), the mean weight loss was ~24.2% over 48 weeks.

Improve blood glucose levels

Lower A1C

Reduce risk of cardiovascular events (heart attack, stroke) in adults with type 2 diabetes and heart disease

Improve blood sugar control

Reduce A1C

Promote healthier insulin response

Lower risk of major cardiovascular events in adults with diabetes and established heart disease

Improve blood sugar control

Lower HbA1c

Enhance insulin response after meals

Reduce the risk of major cardiovascular events (heart attack, stroke) in adults with type 2 diabetes and heart disease

Improve blood sugar control

Lower HbA1c

Reduce glucagon (a hormone that raises blood sugar)

Reduce risk of cardiovascular events (heart attack, stroke) in diabetics with heart disease

Retatrutide activates GLP‑1, GIP, and glucagon receptors.This gives it potential to:

• Suppress appetite (GLP-1)

• Boost insulin secretion (GIP) 

• Increase energy expenditure (glucagon) 

In the key Phase 2 study, participants received 1 mg, 4 mg, 8 mg, or 12 mg of retatrutide once weekly.

The highest tested and most effective dose in that trial was 12 mg/week, and that produced very large weight loss: up to 24.2% body weight after 48 weeks.